PMID-32445447 – BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability

PMID-32445447 – BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability

Park JM, Lee HJ, Sikiric P, Hahm KB. "BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection," Current Pharmaceutical Design, 2020;26(25):2971-2981. doi:10.2174/1381612826666200523180301

Quick Reference

Property Value
PMID 32445447
DOI 10.2174/1381612826666200523180301
Year 2020
Journal Current Pharmaceutical Design
Study Type Narrative Review
Evidence Level V
Sample Review with experimental data on NSAID-induced GI injury models
Peptide(s) Studied BPC-157

Key Findings

  • BPC 157 stabilizes intestinal permeability disrupted by NSAID administration (leaky gut prevention)
  • Protects gastric mucosal cells from NSAID-induced cytotoxicity
  • Enhances cytoprotective mechanisms including tight junction protein expression
  • Counteracts NSAID-induced leaky gut syndrome in preclinical models
  • Demonstrates both preventive and therapeutic efficacy when administered before or after NSAID exposure
  • Notable as a collaboration between Korean (Park, Hahm) and Croatian (Sikiric) research groups

Study Design

Narrative review incorporating experimental data from NSAID-induced GI injury models. Examines both in vivo (animal) and in vitro evidence for BPC 157's cytoprotective mechanisms against NSAID damage. Focuses on intestinal permeability markers and mucosal integrity endpoints.

Limitations

  • Based on preclinical data; no human clinical trials of BPC 157 for NSAID gastroprotection
  • Review format limits systematic evaluation of study quality
  • While co-authored with Korean collaborators, still draws heavily on Sikiric group data

Clinical Relevance

Highly relevant for practitioners whose patients use chronic NSAIDs (a large clinical population). If BPC 157's gastroprotective effects translate to humans, it could serve as an adjunct to NSAID therapy for GI protection — similar to how proton pump inhibitors are currently used. However, human trials are needed before clinical application.

Related

#research #narrative-review #evidence-level-V